Jory Bell

Synthetic Design Lab- a product focused "Smart" therapeutic Technology Platform company building Next Generation Antibody Drug Conjugates (ADCs).

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.

Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research featured on the cover of Science (doi.org/10.1126/science.abe5650), provides new strategies to treat or cure previously-undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people. Were hiring! https://boards.greenhouse.io/atomai

Treating human disease with truly human therapeutics.

Mangata is transforming the way the world interacts with information. Through superior network connectivity that covers the globe, we are going near, far, and beyond. Our technology connects people, machines, and devices across the world through a proprietary network of satellites and terrestrial systems.  Our goal is to build a bridge between connectivity and access, weaving in endless possibilities for businesses and communities to prosper.

Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology.

Strand was founded by biological engineers working together at the Massachusetts Institute of Technology (MIT). Building on the idea of creating smart therapies capable of making sophisticated decisions, they sought to apply this concept to the emerging field of mRNA therapeutics. This area was previously untapped by traditional synthetic biology, leading us to build our very own mRNA programming language, creating the world’s first platform for mRNA smart therapies. Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body via mRNA-encoded logic circuits. These circuits have the ability to implement cell-type specific expressions by sensing and classifying the unique mRNA expression signatures of cells and control the dosage of protein expression through responses to exogenously administered small molecules.

A rocket company at the core, Relativity Space is on a mission to become the next great commercial launch company. With an ever-growing need for space infrastructure, demand for launch services is continuously outpacing supply. Our reusable rockets can meet this demand, offering customers the right size payload capacity at the right cost. Leveraging advances in additive manufacturing, we are strategically focused on reducing vehicle complexity, cost, and time to market. Our patented technologies enable innovative designs once thought impossible and unlock new value propositions in the booming space economy.

Ultima Genomics is unleashing the power of genomics at scale. Our mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.

Velo3D provides a fully integrated metal 3D printing solution for mission-critical parts used for space exploration, to enhance transportation efficiency, and to produce cleaner energy. Our advanced solution helps innovators build the complex parts they need without compromising design or quality, empowering the visionaries of today to build the technologies of tomorrow. @FastCompany World's Most Innovative Manufacturing Companies.

ACROSANCT is a 501(c)3 nonprofit dedicated to the development of high level acrobatic skills and performance under the artistic direction of Master Lu Yi (http://masterluyi.com)

San Francisco based Miselu develops music interfaces and instruments to enrich the experience of creating music with the iPad. The team lead by Yoshinari Yoshikawa and Jory Bell, builds products with a strong design aesthetic, utilizing modern technology in bold new ways to enhance musical expression.

OQO, the industry pioneer in ultra-mobile personal computing, was founded in 2000 by Jory Bell and Jonathan Betts-LaCroix, together with Andrew Popell, Michael Prichard, Nick Merz, and Robert Ford, who set out to shrink a Windows XP personal computer into a pocketable device. Their vision was to transform personal computing in the same way mobile phones revolutionized telecommunications. San Francisco-based OQO demonstrated its initial proof of concept at WinHEC 2002, signaling a new era in ultra-mobile personal computing. OQO unveiled its first commercial product, the OQO model 01, at the 2004 Consumer Electronics Show (CES) where it won awards including TechTV's "Best of Show" in the mobile computing and wireless category. Its successor, the model 01+, was certified by the Guinness World Records, as the world’s smallest full powered, full featured personal computer ever developed. Just recently, OQO announced the new model 2+ with Intel® Atom™ processor, the world’s first PC OLED display, and worldwide 3G capability. Based on the 1.86GHz Intel Atom processor and 2GB RAM, the OQO model 2+ offers performance up to twice as fast as previous devices and includes an embedded touchscreen for easier input. For mobile professionals who need to work on the go, the model 2+ features Qualcomm’s Gobi™ global mobile Internet solution, which supports both of the world’s leading 3G cellular standards. Fundamental to OQO's philosophy is an integrated product development process that focuses on functionality, usability, and design aesthetics. Experts in engineering, sales and marketing, and operations work together from conception through production to rapidly advance the state-of-the-art in PC architecture to meet the professional and personal computing requirements of the mobile enterprise.

Synthetic Design Lab- a product focused "Smart" therapeutic Technology Platform company building Next Generation Antibody Drug Conjugates (ADCs).

Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits to reach previously undruggable patient populations. The current paradigm in genetic medicine relies on developing independent therapies for each separate mutation in the patient population. Founded by pioneers in the CRISPR field from leading institutions for gene editing research, the company is developing a first-of-its-kind RNA writing platform capable of editing thousands of diverse mutations across patients with a single product.

Atomic AI is a well-funded, early-stage biotech company transforming the rational design of molecules and medicines through the cutting-edge fusion of artificial intelligence and structural biology. Atomic’s unique R&D platform, based on research featured on the cover of Science (doi.org/10.1126/science.abe5650), provides new strategies to treat or cure previously-undruggable diseases by targeting RNA structure. We are an interdisciplinary team working across computational and experimental biology and believe that our strongest asset is our people. Were hiring! https://boards.greenhouse.io/atomai

Treating human disease with truly human therapeutics.